Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Penny L Moore

Showing results (71-80 of 215) with videos related to

Pageof 22
Sort By:
Nanotechnology|July 26, 2022
Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoproteinPhindile Ximba, Rosamund Chapman, Ann Meyers, et al.
Journal of Virology|August 21, 2009
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionElin S Gray, Maphuti C Madiga, Penny L Moore, et al.
Journal of Virology|March 2, 2012
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CHazel T Mufhandu, Elin S Gray, Maphuti C Madiga, et al.
Biorxiv : the Preprint Server for Biology|September 19, 2025
BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteinsMohammed El Anbari, Tatsiana Bylund, Sijy O'Dell, et al.
Virology|April 11, 2020
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infectionBongiwe Ndlovu, Kamini Gounder, Daniel Muema, et al.
Frontiers in Immunology|July 24, 2019
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected ChildrenJulia Roider, J Zachary Porterfield, Paul Ogongo, et al.
Plos Pathogens|April 10, 2018
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodiesSimone I Richardson, Amy W Chung, Harini Natarajan, et al.
AIDS (London, England)|September 20, 2017
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responsesCathrine Scheepers, Sudipa Chowdhury, W Shea Wright, et al.
Plos Pathogens|September 19, 2009
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infectionPenny L Moore, Nthabeleng Ranchobe, Bronwen E Lambson, et al.
Plos Pathogens|April 9, 2026
Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIVMark Kowarsky, Mercedes Dalman, Mira N Moufarrej, et al.
Pageof 22

Showing results (71-80 of 215) with videos related to

Sort By:
Pageof 22
Nanotechnology|July 26, 2022
Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoproteinPhindile Ximba, Rosamund Chapman, Ann Meyers, et al.
Journal of Virology|August 21, 2009
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionElin S Gray, Maphuti C Madiga, Penny L Moore, et al.
Journal of Virology|March 2, 2012
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CHazel T Mufhandu, Elin S Gray, Maphuti C Madiga, et al.
Biorxiv : the Preprint Server for Biology|September 19, 2025
BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteinsMohammed El Anbari, Tatsiana Bylund, Sijy O'Dell, et al.
Virology|April 11, 2020
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infectionBongiwe Ndlovu, Kamini Gounder, Daniel Muema, et al.
Frontiers in Immunology|July 24, 2019
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected ChildrenJulia Roider, J Zachary Porterfield, Paul Ogongo, et al.
Plos Pathogens|April 10, 2018
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodiesSimone I Richardson, Amy W Chung, Harini Natarajan, et al.
AIDS (London, England)|September 20, 2017
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responsesCathrine Scheepers, Sudipa Chowdhury, W Shea Wright, et al.
Plos Pathogens|September 19, 2009
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infectionPenny L Moore, Nthabeleng Ranchobe, Bronwen E Lambson, et al.
Plos Pathogens|April 9, 2026
Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIVMark Kowarsky, Mercedes Dalman, Mira N Moufarrej, et al.
Pageof 22